BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) have received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No. CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate.

A first-of-its-kind study published today in AACC’s Clinical Chemistry journal shows that a new protocol for coronavirus testing can increase clinical labs’ testing capacity without sacrificing accuracy

InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden.

DLA Piper represented 4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company serving the life sciences industry, in a growth equity investment of over US$230 million from Goldman Sachs Asset Management.

OpenEye Scientific, an industry leader in computational molecular design, has named Dr. Giovanna Scapin as its newest addition to its Board of Directors.

OpenEye Scientific, developer of the world’s only cloud-native molecular design platform, Orion,™ announced today that it is among the first of only a handful of companies globally that have achieved Amazon Web Services (AWS) High Performance Computing (HPC) Competency status.

CRB, an international leader in sustainable engineering, architecture, construction and consulting solutions to the food and beverage and life sciences industries, today announced the election of four new members to its Board of Directors.

Paradigm4 has launched its REVEALTM: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),today announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration (FDA)for eryaspase in hypersensitive acute lymphoblastic leukemia (ALL) patientsfollowing feedback from the agency in a pre-BLA meeting.

Collegium Pharmaceutical, Inc. announced that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time.